Memorial Sloan Kettering Cancer Center
2020 ASCO Update on Advanced CRC: Is Recently FDA Approved Encorafenib + Cetuximab a New SoC for Previously Treated BRAF V600E-mutant mCRC? Can T-DXd Be an Option for HER2+ Disease?
By
2020 ASCO Virtual Direct™ Highlights
FEATURING
Louise Connell
By
2020 ASCO Virtual Direct™ Highlights
FEATURING
Louise Connell
Login to view comments.
Click here to Login